Your session is about to expire
← Back to Search
SAD Cohorts 1 to 2: Participants receiving ECC4703 for Non-alcoholic Fatty Liver Disease
Study Summary
This trial is testing a new drug, ECC4703, to see if it is safe and effective in healthy volunteers and people with LDL-C levels below 160 mg/dL. The study will give increasing doses of the drug to different groups of people to see what effects it has.
- Non-alcoholic Fatty Liver Disease (NAFLD)
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current status of enrollment in this experiment?
"This study, which originally appeared on clinicaltrials.gov on August 16th 2022 is presently seeking participants. The most recent edit was made to the listing on September 20th 2022."
How many test subjects are taking part in this clinical trial?
"Affirmative. Data found on clinicaltrials.gov attests to the fact that this medical experiment, first published on August 16th 2022, is in need of volunteers. 54 individuals are required to be sourced from a single facility."
Is it possible to join this experiment if you are of legal age?
"This clinical trial is open to participants who are of legal age and have not yet entered their senior years."
Who is the ideal candidate for this medical study?
"This clinical trial demands 54 individuals of age 18-65 suffering from steatohepatitis. The essential criteria are as follows: the participant has BMI between 18 to 32kg/m2; female participants should be postmenopausal, surgically sterile, or use contraception; male participants must also utilize contraception or practice abstinence; no medical complications in physical checkup with 12 lead ECG and vital sign measurements; not utilizing any medication regularly; comprehends and signs informed consent form; fasting LDL cholesterol content is within 100 mg/dL - 159 mg/dL at screening. Moreover, additional inclusion criteria for Part 2 MAD Cohorts B2 to"
Share this study with friends
Copy Link
Messenger